Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WONDERS1: Lepetegravir and Lenacapavir pacfosacil vs Biktarvy in Virologically Suppressed People With HIV-1
NCT06544733Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lepetegravir, lenacapavir pacfosacil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Aug 2024; status: active, not recruiting.
02
Drugs
lepetegravirlenacapavir pacfosacil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06544733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544733.